Rapid Readouts: The SOLO2 / ENGOT Ov-21 Trial

June 25, 2020
Kathleen N. Moore, MD, Stephenson Cancer Center

Related Content:

Rapid ReadoutsOvarian CancerASCO
Pursuing PARP Beyond HRD+ Ovarian Cancer
Utility of HRD Testing in Ovarian Cancer Expands, But Standardization Remains Elusive
Dr. Nakayama on Using Precision Medicine With Mirvetuximab Soravtansine in Ovarian Cancer
x